ClinicalTrials.gg
CompletedNCT05987371Updated Apr 17, 2025

A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

A Phase 2 interventional study of TQC3721 suspension for inhalation and TQC3721 matching placebo for inhalation in Chronic Obstructive Pulmonary Disease, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 11 sites in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-17.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.

Enrollment
11th of 17
75 · median 113
Started
2023
the only one that year
Phase 2
8 of 17
none open now
Registered
4th of 17
by date

Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 11th largest by enrollment, is the only one that started in 2023, is one of 8 in phase 2, and was the 4th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is a phase II clinical trial to evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign an form before the study and fully understand the content, process, and potential adverse reactions of the experiment;
  • Capable of using the study nebulizer correctly and complying with all study restrictions and procedures;
  • Aged between 30 and 75 years old (Including critical values), both men and women;
  • (BMI) within the range of 18-30 kg/m2 (Including critical values);
  • The subject has no pregnancy plan and voluntarily adopts effective measures for at least one month from screening until the last use of the study drug;
  • Diagnosed as a patient according to the Global initiative for chronic obstructive lung disease (GOLD) 2023 standard, and had symptoms that met COPD for at least 1 year before screening;
  • Able to conduct acceptable and repeatable lung function measurements;
  • Clinical stability of COPD within 4 weeks before screening visit (V1) and between V1 visit and V2 visit;
  • Long acting Bronchiectasis or short acting Bronchiectasis were not regularly used at least 14 days before screening visit (V1);
  • Long acting Bronchiectasis can be stopped during the study until the end of the study, and short acting Bronchiectasis can be stopped at least 6 hours before the pulmonary function test;
  • Meet the restrictions on combination medication and expect to maintain the restrictions during treatment;
  • Current smoking or smoking history ≥ 10 pack years (smoking at least 20 cigarettes per day for 10 consecutive years or smoking at least 10 cigarettes per day for 20 consecutive years, former cigarette smokers must stop smoking>6 months before visit 1).

Exclusion criteria

Exclusion Criteria:

  • A history of life-threatening , including hospitalization in an intensive care unit and/or the need for intubation.
  • Acute exacerbations of COPD requiring oral or parenteral treatment within 3 months before screening (V1) or before randomization (V2).
  • Received inhaled corticosteroids (ICS) treatment within 4 weeks prior to screening.
  • Have a history of hospitalization for COPD at least once within 6 months prior to screening.
  • Antibiotic treatment for upper and/or lower respiratory tract infection within 6 weeks before screening or before randomized visit (V2). Note: Patients with a history of upper/lower respiratory tract infection within 6 weeks cannot participate in the test, but can be re-screened 6 weeks after the infection is cured.
  • COVID-19:

    1. Suspected or confirmed COVID-19 infection during screening (V1), confirmed by the laboratory or based on the medical judgment of the researcher; Subjects who are known to have contact with COVID-19 positive patients. Note: Subjects should remain Asymptomatic for 14 days or more after exposure, and only after being approved by the investigator can they be re-screened.
    2. Known COVID-19 infection history within 4 weeks before screening (V1);
    3. Known medical history of hospitalization due to COVID-19 within 3 months before screening (V1);
    4. Subjects who had COVID-19 infection before screening (V1) and had not fully recovered to participate in clinical trial operations.
  • Suffering from other respiratory diseases simultaneously: α- 1. Antitrypsin deficiency, primary ciliary dyskinesia, lung cancer; Respiratory diseases such as active pulmonary infection, pulmonary tuberculosis, Bronchiectasis, Pulmonary fibrosis, pulmonary Sarcoidosis, pulmonary hypertension, etc. with significant clinical significance assessed by the researchers.
  • Chest computed tomography (CT) has found abnormalities and believes that the abnormalities are not caused by COPD, and the researchers have determined that they have an impact on the trial results or patient safety. If there is no chest CT report within 3 months before visit 1, a chest CT examination must be performed on visit 1.
  • Previously underwent pneumonectomy or lung reduction surgery.
  • Previously received lung rehabilitation treatment (those who have been stable for 4 weeks before screening and have remained stable during the trial period can be selected).
  • Received oral steroids or roflumilast treatment for COPD within 3 months before screening (Visit 1), or received oral theophylline and/or theophylline derivatives treatment for COPD within 1 months before screening (V1).
  • Use non-selective oral administration β Receptor blockers.
  • Previously received treatment with ensifentrine and HRS-9821.
  • Patients receiving immunotherapy (such as Azathioprine and Cyclophosphamide) within 4 weeks before the screening period.
  • The researcher evaluated that during the screening and treatment stages of this study, patients were unable to discontinue the prohibited drugs specified in the protocol.
  • The patient has a history of diseases that cannot be controlled at present, including but not limited to diseases of endocrine, thyroid, nervous system, liver, gastrointestinal tract, kidney, blood, Urinary system, immunology or ophthalmic diseases which the investigator judges are clinically significant.
  • History or current evidence of cardiovascular diseases with clinical significance. It is defined as any disease that the investigator believes will endanger the safety of patients when participating in the study, or any disease that may affect the effectiveness or safety analysis if the disease/condition worsens during the study; Subjects who have experienced any of the following conditions during visit 1 will be excluded:

    1. myocardial infarction, unstable angina, or stroke within the past 6 months;
    2. There have been unstable or life-threatening arrhythmia requiring intervention within the past 3 months;
    3. (NYHA) III-IV Heart Failure.
  • Have unstable or uncontrollable hypertension.
  • Major surgery (requiring general anesthesia) was performed within 8 weeks before the screening visit (V1), or the patient did not fully recover from the surgery during the screening visit (V1), or surgery was planned before the end of the study.
  • A history of cured or uncured malignant tumors in any organ or system in the past 5 years.
  • Intolerance or allergy to Salbutamol or TQC3721.
  • Those who require oxygen therapy, even occasionally.
  • Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • Persons who have received within 28 days before randomization, Inactivated vaccine within 7 days, or who plan to receive vaccination during the study period.
  • Have a history of drug or alcohol abuse within the past 3 years.
  • Individuals who have participated in any clinical trial of drugs or medical devices within 4 weeks or 5 drug half-lives (whichever is longer) prior to screening.
  • The researcher believes that there are other situations that are not suitable for participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    TQC3721 Suspension for Inhalation (Twice a day)+ Salbutamol

    TQC3721 suspension for inhalation, twice a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.

    Drug: TQC3721 suspension for inhalation · Drug: Salbutamol sulfate inhalation aerosol

  • Experimental
    TQC3721 Suspension for Inhalation (Once a day)+ Salbutamol

    TQC3721 suspension for inhalation, once a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.

    Drug: TQC3721 suspension for inhalation · Drug: Salbutamol sulfate inhalation aerosol

  • Placebo comparator
    TQC3721 matching placebo for inhalation (Twice a day)+ Salbutamol

    TQC3721 suspension placebo for inhalation, twice a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.

    Drug: TQC3721 matching placebo for inhalation · Drug: Salbutamol sulfate inhalation aerosol

  • Placebo comparator
    TQC3721 matching placebo for inhalation (once a day)+ Salbutamol

    TQC3721 suspension placebo for inhalation, once a day for 4 weeks, Salbutamol sulfate inhalation aerosol is used as required.

    Drug: TQC3721 matching placebo for inhalation · Drug: Salbutamol sulfate inhalation aerosol

Interventions

  • TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.

  • DrugTQC3721 matching placebo for inhalation

    Placebo without active substance.

  • DrugSalbutamol sulfate inhalation aerosol

    Salbutamol is short-acting β2 receptor agonists.

06

What researchers measure

Primary outcomes

  1. The peak of Forced Expiratory Volume in the 1st second (FEV1) (4 weeks)

    Change of the maximum value of FEV1 from baseline to four weeks after treatment

    Time frame: From baseline to four weeks after treatment.

Secondary outcomes

  1. Morning trough FEV1

    The FEV1 before administration

    Time frame: From baseline to four weeks after treatment.

  2. Average FEV1 (4 weeks)

    Average FEV1 of 3 hours, 12 hours, 24 hours, 0-12 hours and 12-24 hours after administration.

    Time frame: From baseline to four weeks after treatment.

  3. Changes in FEV1

    Changes in FEV1 at each time point within 24 hours after administration

    Time frame: From baseline to four weeks after treatment.

  4. COPD Assessment Test (CAT)

    Change From Baseline to four weeks after treatment. The score range is 0 to 40 points (0 to 10 is minor influence; 11 to 20 are moderate; 21 to 30 are classified as severe impact; 31 to 40 is very severe).

    Time frame: From baseline to four weeks after treatment.

  5. Modified Medical Research Council (mMRC) Dyspnea Scale Score

    Change From Baseline to four weeks after treatment in mMRC Scoring. The questionnaire is mainly used to evaluate the degree of respiratory distress in patients with chronic obstructive pulmonary disease. According to the symptoms of respiratory distress, the questionnaire is divided into 5 levels, with 0-1 points as less symptoms and ≥ 2 points as more symptoms.

    Time frame: From baseline to four weeks after treatment.

  6. The peak of FEV1 (two weeks)

    Change of the maximum value of FEV1 from baseline to two weeks after treatment

    Time frame: From baseline to two weeks after treatment.

  7. Trough FEV1

    Change of trough FEV1 from baseline to two weeks after treatment.

    Time frame: From baseline to two weeks after treatment.

  8. Average FEV1 within 3 hours

    Average FEV1 within 3 hours after administration

    Time frame: From baseline to two weeks after treatment

  9. Frequency of Rescue medication

    Frequency of Rescue medication used group during the study in the experimental compared to that in the placebo group.

    Time frame: From baseline to four weeks after administration.

  10. Plasma drug peak concentration (Cmax)

    Plasma drug peak concentration after administration.

    Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.

  11. Time to maximum concentration (Tmax)

    Time to maximum concentration (Tmax) after administration.

    Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.

  12. Area Under Curve (AUC)

    Area under the drug concentration-time curve.

    Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.

  13. Elimination half-life (t1/2)

    Apparent terminal elimination half-life after drug administration.

    Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.

  14. Apparent volume of distribution (Vd)

    Apparent volume of distribution after drug administration.

    Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.

  15. Clearance (CL)

    The total drug clearance rate of liver, kidney, etc.

    Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.

  16. Plasma concentration at steady state (Cav, SS)

    The plasma concentration at which the rate of administration and rate of elimination are in equilibrium.

    Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.

  17. Minimum concentration (Cmin)

    Plasma drug minimum concentration after administration.

    Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.

  18. Degree of fluctuation (DF)

    The ratio of the difference between Cmax,ss and Cmin,ss to Cav,ss.

    Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.

  19. Steady state volume of distribution (Vss)

    Steady state volume of distribution after administration.

    Time frame: Within 60 minutes before administration on Day 1, to 24 hours after administration on Day 28.

  20. Number of cases of adverse events

    Number of cases of adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.

    Time frame: From baseline to four weeks after treatment.

  21. Incidence of adverse events

    Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.

    Time frame: From baseline to four weeks after treatment.

  22. Number of cases of serious adverse events.

    Number of cases of serious adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.

    Time frame: From baseline to four weeks after treatment.

  23. Incidence of serious adverse events.

    Incidence of serious adverse events assessed by Common Terminology Criteria for Adverse Events ( CTCAE ) v5.0.

    Time frame: From baseline to four weeks after treatment.

  24. Number of cases of adverse events related to study drug.

    Number of cases of adverse events related to study drug assessed by CTCAE v5.0.

    Time frame: From baseline to four weeks after treatment.

  25. Incidence of adverse events related to study drug.

    Incidence of adverse events related to study drug assessed by CTCAE v5.0.

    Time frame: From baseline to four weeks after treatment.

  26. The peak of FEV1 (Day 1).

    Change of the maximum value of FEV1 from baseline to Day 1.

    Time frame: From baseline to Day 1.

  27. The peak of FEV1 (Day 1 to 4 weeks)

    Change of the maximum value of FEV1 from Day 1 to four weeks after treatment

    Time frame: From Day 1 to four weeks after treatment.

  28. Average FEV1 (Day 2)

    Average FEV1 of 3 hours, 12 hours, 24 hours, 0-12 hours and 12-24 hours after administration.

    Time frame: From baseline to 24 hours after first treatment.

  29. Average FEV1 (Day 1 to 4 weeks)

    Average FEV1 of 3 hours, 12 hours, 24 hours, 0-12 hours and 12-24 hours after administration.

    Time frame: From Day 1 to four weeks after treatment.

07

Study locations

11 sites
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510000, China
  • The Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong 524023, China
  • Wuhan Sixth Hospital
    Wuhan, Hubei 430015, China
  • Changsha Third Hospital
    Changsha, Hunan 410035, China
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225000, China
  • People's Hospital of Jiangxi province
    Nanchang, Jiangxi 330006, China
  • The first hospital of Jilin University
    Changchun, Jilin 130021, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610044, China
  • Mianyang Central Hospital
    Mianyang, Sichuan 621099, China
  • Suining Central Hospital
    Suining, Sichuan 629000, China
  • The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325088, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jan 2024, 4 months.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 4 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2023
First posted
Aug 14, 2023
StartActual
Aug 23, 2023
Primary completionActual
Jan 16, 2024
CompletionActual
Apr 23, 2024
Last update
Apr 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05987371
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Aug 23, 2023
Primary completion
Jan 16, 2024
Completion
Apr 23, 2024
Last update
Apr 17, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC3721

Start the discussion